Drug Type Antibody |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Preclinical | CN | 16 Jun 2024 | |
Inflammatory Bowel Diseases | Preclinical | CN | 16 Jun 2024 | |
Multiple Sclerosis | Preclinical | CN | 16 Jun 2024 | |
Primary Biliary Cholangitis | Preclinical | CN | 16 Jun 2024 | |
Rheumatoid Arthritis | Preclinical | CN | 16 Jun 2024 | |
Systemic Lupus Erythematosus | Preclinical | CN | 16 Jun 2024 |